Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monika Engelhardt

Showing results (51-60 of 226) with videos related to

Pageof 23
Sort By:
Experimental Hematology|September 25, 2007
Characterization of in vitro growth of multiple myeloma cellsMihaela Zlei, Sabine Egert, Dagmar Wider, et al.
Onkologie|December 14, 2011
Does colorectal cancer in ulcerative colitis patients constitute a risk for chemotherapy refractoriness?:a systemic approach by detailed analysis via the electronic tumor base documentation systemMonika Engelhardt, Gabriele Ihorst, Josefina Udi, et al.
Blood|September 5, 2002
Severe cold hemagglutinin disease (CHD) successfully treated with rituximabMonika Engelhardt, Andreas Jakob, Björn Ruter, et al.
Cancer|May 28, 2020
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patientsMaximilian Schinke, Gabriele Ihorst, Justus Duyster, et al.
Leukemia Research|October 12, 2004
Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine)Michael Lübbert, Michael Daskalakis, Regina Kunzmann, et al.
Deutsches Arzteblatt International|March 22, 2022
Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined SignificanceVanessa Piechotta, Nicole Skoetz, Monika Engelhardt, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2011
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisalMartina Kleber, Gabriele Ihorst, Josefina Udi, et al.
Clinical Nuclear Medicine|May 27, 2022
Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential?Kerstin Michalski, Cordula A Jilg, Monika Engelhardt, et al.
Leukemia|July 28, 2023
Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensusEvangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Annals of Hematology|July 4, 2012
Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and toleranceJulia Horn, Martina Kleber, Stefanie Hieke, et al.
Pageof 23

Showing results (51-60 of 226) with videos related to

Sort By:
Pageof 23
Experimental Hematology|September 25, 2007
Characterization of in vitro growth of multiple myeloma cellsMihaela Zlei, Sabine Egert, Dagmar Wider, et al.
Onkologie|December 14, 2011
Does colorectal cancer in ulcerative colitis patients constitute a risk for chemotherapy refractoriness?:a systemic approach by detailed analysis via the electronic tumor base documentation systemMonika Engelhardt, Gabriele Ihorst, Josefina Udi, et al.
Blood|September 5, 2002
Severe cold hemagglutinin disease (CHD) successfully treated with rituximabMonika Engelhardt, Andreas Jakob, Björn Ruter, et al.
Cancer|May 28, 2020
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patientsMaximilian Schinke, Gabriele Ihorst, Justus Duyster, et al.
Leukemia Research|October 12, 2004
Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine)Michael Lübbert, Michael Daskalakis, Regina Kunzmann, et al.
Deutsches Arzteblatt International|March 22, 2022
Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined SignificanceVanessa Piechotta, Nicole Skoetz, Monika Engelhardt, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2011
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisalMartina Kleber, Gabriele Ihorst, Josefina Udi, et al.
Clinical Nuclear Medicine|May 27, 2022
Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential?Kerstin Michalski, Cordula A Jilg, Monika Engelhardt, et al.
Leukemia|July 28, 2023
Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensusEvangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Annals of Hematology|July 4, 2012
Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and toleranceJulia Horn, Martina Kleber, Stefanie Hieke, et al.
Pageof 23